REPL shares surge 137% premarket after the FDA's panel of outside advisers voted to back results from a trial studying the company's drug fo

REPL shares surge 137% premarket after the FDA's panel of outside advisers voted to back results from a trial studying the company's drug for a type of skin cancer. REPL seeks accelerated approval for RP1 in combination with BMY's Opdivo in advanced melanoma in patients whose tumors grew despite prior treatment, with a decision expected by August 2